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Evidence for Effects of Chronic Lead
Exposure on Blood Pressure in
Experimental Animals: An Overview
by Winona Victery*
Information obtained in a number of experimental studies conducted over the last 40 years on the
effects of lead on blood pressure is reviewed. Differences in animal species, age at beginning of
exposure, level oflead exposure, indices oflead burden, and blood pressure effects ofeach study are
reported. In several of the high-dose experiments, hypertension was observed, but nephrotoxicity of
lead may have contributed to its development. Moreover, in other high-dose experiments, no
hypertension was observed, and in at least one experiment, the evidence suggested that lead could
reduce an elevated blood pressure. In contrast, the lower dose experiments consistently
demonstrated a hypertensive effect. Overall, the data suggest a biphasic dose response.
Establishment of an appropriate animal model to study blood pressure effects of lead will require
careful assessment of dietary interactions with lead, unstressed blood pressure monitoring with
standardized techniques, and documentation of biologically effective lead burden. Future research
should examine lead exposure at more environmentally appropriate levels in order to deternine the
validity ofassociating this pollutant with blood pressure effects in the human population.
Introduction
The literature reporting effects of lead exposure on
blood pressure in experimental animals is scattered
among international journals and proceedings over at
least a 40-year period; in many cases, the authors'
knowledge of similar or divergent experimental
findings was not noted. It is not surprising that the
results sometimes appear inconsistent. The purpose of
this paper is to review these studies, examining the
lead dose, route of exposure, age at initiation of expo-
sure, when the effects were first observed, how long the
animals were followed, and any indication of the
internal lead burden. These findings will orient the
reader to the papers in this issue, which discuss several
possible targets of lead's cardiovascular toxicity.
An underlying question for most researchers is
whether the lead dose administered should be of
sufficient magnitude to induce nephrotoxicity prior
to the onset of hypertension or if hypertension may
develop prior to renal damage. Over the years, the
experimental lead dose range for rats has varied
between 70 mg per day (1,2) and 3.0 ,ug per day in
animals consuming approximately 30 mL of 0.1 ppm
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lead in drinking water (3). Clearly, in the former case
it is likely that renal pathology can be, observed, while
in the latter, only subtle renal changes are observed.
The route of administration varies somewhat
among studies, but it is usually oral (by gavage, in
drinking water, or mixed in the food). The amount
absorbed varies widely and depends on other nutri-
tional factors and the age of the animal. The length of
time for which exposure continues has been between 2
months and 2 years. The length of exposure before ini-
tiating monitoring and for continuation of moni-
toring varies greatly; in fact, some investigators have
not followed a large enough group of control and ex-
perimental animals to detect statistical significance
between the groups. Blood pressure monitoring is
usually performed indirectly (by tail cuff plethys-
mography), either on the anesthetized or unanesthe-
tized animal, or directly by insertion of an arterial
catheter and detection by a pressure transducer. For
repeated measurements in the same animal, the
plethysmography is preferable but has the disad-
vantage that the animals are prewarmed, which is
enough of a stress that some lead-exposed rats did not
survive this procedure (4). If the animals are unanes-
thetized, they must be conditioned to the restrainer so
that unstressed values are obtained. Anesthetics also
affectthe blood pressure, so that this stress must also be
evaluated. At the termination of the exposure period, itW VICTERY
is quite helpful to have a direct blood pressure mea-
surement to correlate with the indirect measurements
previously obtained.
Species studied include rats, dogs, and pigeons. Sex
of the animal may have a role in determining sus-
ceptibility to cardiovascular toxicity of lead, although
this has not been clearly established. Animal housing
and handling conditions are especially important if
the animals are to be monitored in the unanesthetized,
unstressed state. Indicators of the body burden of lead
(such as blood or kidney lead concentrations) have
frequently notbeen performed; ifso, the extent ofa dose-
response relationship between the amount of lead
administered, blood lead, and blood pressure changes
could be quantified.
Table 1. Summary ofstudies relating chronic, high-level lead exposure to blood pressure effects in rats.
Age
[PbB], exposure Duration Effects on
Reference Species n Lead exposure pg/dLa begun ofexposure blood pressure Renal effects
(1) Rats 15 70mg/daygavage, - Adults 30-80 days All that survived Not studied
6times/week (150-200 g) 40 days were
hypertensive
(2) Rats 11/30
(survived
60 days)
70mg/day,
gavage, 6
times/week
(5) Rats 30 35 mg/100g
3 times/week
for 9weeks;
140 mg/100 g
3 times/week
for 10weeks by
stomach tube
(7) Rats 5-10
animals
/dose
10,b 20, 40 mg
lead phosphate/
week, SC
Young
- Adults
(250g)
Adult
(6) Rats, 10 exposed 40 mg/dayfor Control: 18
male 9 control 30 daysgavage, Exposed: 76
80mg/daygavage
also 1.5%lead acetate
in drinking water
(9) Rats 9exposed 10,000 ppm
5 controls in drinking
water
17.0
23.5
50 days 10/11 were hyper-
tensive at 45 and
60 days (mean
146 ± 7.6 and 182.2
+ 6.6, respectively)
224 days No effectunder
total etheranesthesia;
however, both con-
trols and exposed
were elevated
23weeks; 20 mg: > 130mm
60weeks Hgunder ether
anesthesia; 40 mg
"too toxic"
Not stated 173 days
Weaning 6 weeks
Higher in controls
over entire period
19 weeks after
exposure ended,
systolic increased
13mmHg
Some gross
pathologic
changes; intra-
nuclear inclu-
sion bodies in
renal tubular
epithelium; no
histologic changes
in arterioles,
arteries ofkid-
neys and other
organs
Increased kid-
neyweight, at
135-152 days,
histologic
changes in
tubules; no effect
on GFR; 21%
increase inTm
PAH for 100
days, then fell to
pretreatment
value
Hypertrophy of
arterioles in
kidneys, other
organs
No change in BUN,
proteinuria, con-
centratingability,
intranuclear
inclusion bodies
in proximal
tubular
epithelium
Decreased GFR,
both whole kid-
ney and single
nephron; also
decreased renal
bloodflow, de-
crease in func-
tion ofboth
superficial and
deep nephrons
a[PbBJ, blood lead concentration.
bRats exposed to 10 mg lead served ascontrols.
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Experimental Findings
Table 1 presents a brief summary of the literature
citations in which rats were administered relatively
high lead doses. The experiments of Griffiths and
Lirdauer (1) and Diaz-Rivera and Horn (2) used
similar protocols, administering 70 mg of lead per day
by gavage to rats; this dose produced hypertension in
animals that survived the dosing period. Nephrotoxic
effects were clearly observed in the animals that were
examined. Pardoe (5) and Padilla et al. (6) also used
similar protocols (30 to 40 mg for the initial dose, with
even higher doses in the subsequent exposure period).
The lead exposure did not elevate blood pressure with
respect to controls; there were marked changes in renal
histology, although there were no decrements in
several measured parameters of renal function. Pardoe
reported that the tubular transport maximum for p-
aminohippuric acid (PAH) was elevated by 20% at 3
months, indicating an increase in tubular excretory
function that paralleled the increase in kidney weight.
This effectappeared to be reversible in the laterperiod of
the experiment. Of the earlier experiments, Padilla et
al. (6) are the only authors to report blood lead concen-
trations; however, the validity of the blood lead analy-
sis appears questionable considering both the high
control values and the relatively low values in the
exposed group. The paper with the most relevance for
comparison to more recent studies is that of Cottier et
al. (7). Lead phosphate in a dose of 20 mg per week ad-
ministered SC elevated systolic pressure above 130 mm
Hg. Lead phosphate contains 76% lead, which would be
equivalent to 15 mg lead per week. Twice this dose (40
mg/week) was "too toxic." In the report (to be described
later) by Victery et al. (8), a rat consuming 100 ppm
lead in drinking water might average 30 mL/day x 7
days/week, or 21 mg/week. Extrapolation between
these two papers should be performed with caution to
the different routes of administration (SC vs. oral).
There are no reported blood lead values in the Cottier
paper.
The last paper in this group (9) used a very different
treatment protocol: 1% lead was administered for 6
weeks and the blood pressure and renal function tests
were performed 19 weeks later. Mean blood lead con-
centration exceeded 150 ,ug/dL at the end of exposure
and fell to 24 tg/dL at the time of the procedure. Blood
pressure was elevated by 13 mm Hg and there were
decreases in whole kidney glomerular filtration rate
(GFR) and single nephron GFR, as well as decreases
in renal plasma flow.
Table 2 presents the more recent experimental reports
ofblood pressure effects when lower levels oflead expo-
sure was used beginning as early as in utero. A similar
presentation of this information is incorporated in the
comprehensive review paper of Sharp et al. (10). Perry
and Erlanger (3) report initial results from a large
series of studies. The most striking findings from
among the published reports from this group are that
significant increases in systolic blood pressure are
Table 2. Summary ofblood pressure studies with low-level, chronic exposure.
Lead Age
exposure, [PbB], exposure Duration Effects on systolic
Reference Species n ppm pg/dLa begun ofexposure blood pressure Renaleffects
(3) Rats, female 45 0 Weaning 18 months At 5ppm, 12-14 Notstudied
15 0.1 mm Hggreater
15 1.0 - than controls,
15 5.0 lightly anesthe-
tizedwith pento-
barbital
(11) Rats, male 15 0 13.6 Adult 160-180day Increase of54 Notstudied
50.0 38.4 mm Hgsystolic
fromcontrols under
pentobarbital
anesthesia
(8) Rats, male 19 0 2.2 In utero 6months Unanesthetized at Increased kidney
19 100 40.4 In utero 3.5 months, weightwith
13 500 70.8 In utero 100-ppm animals both intra-
increase of17 nuclear inclu-
mm Hg; no change sionbodies
in 500ppm with 500ppm;
no evidence of
renal disease
(17) Rats, male 20 0 In utero 5 months No difference Notstudied
20 5 5.6
13 25 18.2
(12) Rats, male 10 0 - Weaning 180 days Pentobarbital Notstudied
10 50 anesthesia,
48 mm Hg increase
a[PbBJ, blood leadconcentration.
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found in rats exposed to as little as 0.1 ppm lead in the
treatment drinking water, with a dose-dependent rela-
tionship holding for the higher exposure regimens
(up to 5 ppm). All animals were fed a rye-based diet
with low levels of trace minerals; mineral supplements
were present in the drinking water. However, no blood
lead values were obtained.
In the early 1980s, a number of similar studies were
performed by a group of Italian scientists and by
Vander and colleagues at the University of Michigan.
Rats were exposed to doses of lead between 5 and 500
ppm in the drinking water. The studies reported by
lannaccone et al. (11) and Carmignani et al. (12) used
50 ppm beginning at weaning to 6 months of age.
Under pentobarbital anesthesia, these animals had an
approximate 50-mm Hg increase in blood pressure
compared to controls and were studied for a number of
other cardiovascular parameters, some of which are
discussed in the papers published in this volume (13-
16). Blood pressure was not followed over time, so it is
not known when the pressure change occurred or
whether there was evidence of a dose-response rela-
tionship. Blood lead values for the 50-ppm lead-exposed
group were approximately 40 ,ug/dL, compared to 14
,ug/dL for controls, as reported by lannaccone (10).
In the Michigan studies reported by Victery et al.
(8,17), 0, 5, and 25 ppm lead in drinking water was
administered to rats beginning in utero and con-
tinuing to 5 to 6 months of age in one study, and 100
and 500 ppm doses were used in the other. Blood pres-
sure was monitored approximately every 2 weeks in
conscious, restrained rats by tail cuff plethysmog-
raphy. Although no changes in blood pressure were
detected in the lower dose experiments, there were sig-
nificant changes in the renin-angiotensin system of
25-ppm animals (15). Blood lead concentrations aver-
aged 5.6 and 18.2 pg/dL for the 5- and 25-ppm animals,
respectively. Exposure to 100 ppm (but not 500 ppm)
produced a significant 17-mm Hg elevation in blood
pressure beginning at 3 1/2 months of age and con-
tinuing until 6 months of age. Renal function was not
evaluated. Kidney weights were significantly elevated
at 100 ppm, and some morphologic changes were
observed at 500 ppm. Blood lead levels averaged 40
,ug/dL for 100 ppm and 70gg/dL for 500 ppm.
Table 3 presents the results of two recent studies eval-
uating the effects of lead on the cardiovascular system
of rats of the spontaneously hypertensive strain (SHR).
The paper by Wiecek et al. (18) reports a lead dose-
dependent decrease in blood pressure in the SHR rats
and control (WKR) rats, and the authors conclude
that their findings are contradictory to the findings of
Victery et al. (8,17). However, the findings are not
contradictory because it appears that these authors
have made a mistake in calculation of the lead dose
used by Victery et al. and actually treated their animals
with 2.5 to 50 times higher doses than our hyper-
tensive dose. This is verified by their statement that
blood lead values in their rats were "much higher"
than those reported byVictery et al. (8,17).
In another study, Evis et al. (4) administered lead (at
250 and 1000 ppm) to SHR and control rats. The
authors evaluated a number of cardiovascular pa-
rameters including conscious and anesthetized blood
pressure. The higher dose of lead significantly in-
creased blood pressure in both groups of rats, which
had reported blood lead concentrations of 40 ,ug/dL.
Interestingly, lead accelerated the development of
hypertension in the SHR animals and also increased
their sensitivity to the warming required for dilation
of the tail artery used for measuring conscious blood
pressure (seven of eight animals died).
Results obtained in other species (pigeons and dogs)
are summarized in Table 4. In pigeons (19), a low dose
of lead (in combination with a number of other di-
etary parameters) produced a significant elevation in
Table 3. Summary ofeffects oflead exposure on blood pressure in spontaneously hypertensive rats.
Lead Age
exposure, [PbB], exposure Duration Effects on blood
Reference Species n ppm pg/dLa begun ofexposure pressure Renal effects
(18) Rat 7 0 Significant dose- Not studied
WKR 11 250 dependent decrease
11 1250 underlightether
SHR 11 2500 "Veryhigh" 3 months 10 weeks anesthetized or con-
11 5000 scious instrumented
rat
(4) Rat 10-15/ 0 Beginning at 5 weeks Not studied
dose 250 19.9 Weaning 3 months ofexposure,
1000 43.7 significantly elevated
in SHRand Sprague-
Dawley rats. At 12
weeks, 1000 ppm
Normoten- 10-15/ 0 From 3 months anesthetized
sive Sprague- dose 250 17.0 conception post Sprague-Dawley rats
Dawley, male 1000 38.1 weaning had 15 mm Hg
increase in systolic
prior to cardiac
studies
aIPbB], blood lead concentration.
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Table 4. Summary ofeffects ofchronic lead exposure on blood pressure in other species.
Age
Lead [PbB]a exposure Duration Effects on blood
Reference Species n exposure Vig/dL begun ofexposure pressure Renal effects
(19) Pigeon male, - 0.8 ppm - 6 months 3 months 20 mm Hg Not studied
increase in
systolic
(20) Dog, female 2 32.5 gfor - 160weeks 1 year None Not studied
160weeks;
1.9g died
during short
exposure
(21) Dog, female 3 0 9.2 5 months 3 months 12 mm Hg No difference
3 1 mg/kg daily 35.8 increase in in extracellular
mean arterial fluid, plasma
pressure volume, GFR,
serum creati-
nine, or renal
plasmaflow
aPbBI, blood lead concentration.
blood pressure, which could be alleviated by increasing
the calcium concentration in the drinking water. The
exposure of two dogs to very high levels of lead did not
invoke an increase in blood pressure but did produce
acute episodes oflead poisoning (20). In a paper by Fine
et al. (21), three young dogs received a low dose oflead
(1 mg/kg daily, blood lead concentration of 36 ig/dL)
and were found to develop a persistent (from 10 days to
20 weeks) 12-mm Hg increase in mean arterial pres-
sure when compared to their paired control dogs.
Additional determinations of the renin profile show
that renin is initially elevated (at 28 days exposure)
but then returns to normal levels while blood pressure
remains elevated.
Conclusions and Directions for
Future Research
This short overview illustrates the complexity of
interpreting data from experimental models that have
been used to evaluate the relationship of lead exposure
at different levels to changes in blood pressure. Based
on the collective results of the studies reviewed, it
appears that lead administered at relatively nontoxic
levels produces an elevation in blood pressure that is
sustained over a considerable portion of the animal's
life span. In contrast, high doses are not consistently
associated with hypertension and may actually lower
blood pressure. Could this be related to certain protec-
tive or adaptive mechanisms reducing lead's effects or
to an effect on the general health of the animals? In any
case, these high doses may not be relevant to the hu-
man situation. For the experimental literature to be
specifically relevant to human environmental expo-
sures, findings of alterations in cardiovascular
parameters in the blood lead range of 5 to 40 ,ug/dL
would be most suitable.
A number of blood pressure regulatory control
systems have been shown to be altered by various lead
exposure protocols. These include several hormone and
neurobehavioral regulatory systems, changes in vas-
cular smooth muscle reactivity, cardiac muscle con-
tractility, changes in cell membrane cation transport
systems, and possible effects on vascular endothelial
cells. Changes in at least one ofthese systems have been
reported at all of the lower lead dose ranges, with some
exceptions at higher doses. Which systems are most
important contributors to a significant, persistent ele-
vation in blood pressure have not been established
definitively. There may be a number of sequential
changes that occur and are no longer observable de-
pending on the time of examination. However, it
appears that there are sufficient experimental data
available to confirm that chronic lead exposure at low
levels can affect blood pressure levels in a consistent
fashion.
Inevitably, the dose range and shape of the dose-
response curve become issuesfordebate because they are
relevant to the question of whether or not the lead
exposure range is comparable to that of the general
human population or only to those individuals occu-
pationally exposed to lead. It appears from some experi-
mental studies that the blood pressures measured at
higher doses are lower than would be expected, sug-
gesting a biphasic dose-response curve.
The exact dose-response range for this finding has
not been well established, primarily because of different
methodology used by each group of investigators. A
standardized protocol for preparing and admin-
istering the lead dose, dietary components, rat strain,
and age-at-initiation of exposure should be developed.
Methodology for measuring blood pressure on a con-
tinuing basis in the conscious animal has improved
so that tail cuff measurements can be performed with-
out warming, and recordings can be obtained on
several animals at once. These techniques should be
applied in a carefully controlled setting along with
validation of the biological markers of lead exposure.
Once these conditions have been well established,
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other important questions should be addressed. These
include: Can the effect on adult blood pressure be estab-
lished by an early exposure period at environmentally
appropriate levels? Can the effect on blood pressure be
reversed by removal of the lead source and reducing
the lead burden? Answers to these questions would be
valuable because they would help to evaluate the need to
continue reductions in environmental lead exposure
to the human population.
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